Table 2 Grade 3 or higher toxicities, readmission rates and mortality during the neoadjuvant treatment of patients with pancreatic adenocarcinoma
Grade 3 or higher toxicities | Number of studies reporting the studied outcome | % | 95% confidence interval |
|---|---|---|---|
Overall | 39 | 36% | 27–45% |
Hematologic | 16 | 25% | 14–38% |
Anemia | 33 | 4% | 3–6% |
Leukopenia | 26 | 25% | 18–32% |
Lymphopenia | 8 | 13% | 4–24% |
Neutropenia | 38 | 23% | 17–29% |
Febrile neutropenia | 17 | 3% | 1–5% |
Thrombocytopenia | 41 | 7% | 5–10% |
Non hematologic | 17 | 16% | 7–27% |
Nausea/vomiting | 40 | 7% | 4–10% |
Diarrhea | 38 | 4% | 2–6% |
Anorexia | 19 | 3% | 1–6% |
Fatigue | 26 | 4% | 1–7% |
Biliary obstruction/cholangitis | 22 | 5% | 3–7% |
GI bleed, gastritis, or duodenitis, | 14 | 3% | 1–7% |
Hospitalization rate | 15 | 21% | 14–27% |
% of patients completing neoadjuvant therapy | 42 | 90% | 87%–93% |
Mortality | 48 | 0% | 0–1% |